Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
BIIB

Biogen Inc

BIIB

239.29USD+0.17 (+0.07%)Market Closed
Watchlist

Market Summary

USD239.29+0.17
Market Closed
0.07%

BIIB Alerts

  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

BIIB Stock Price

View Fullscreen

BIIB RSI Chart

BIIB Valuation

Market Cap

34.6B

Price/Earnings (Trailing)

23.69

Price/Sales (Trailing)

3.46

EV/EBITDA

16.91

Price/Free Cashflow

32.62

BIIB Price/Sales (Trailing)

BIIB Profitability

EBT Margin

16.10%

Return on Equity

10.1%

Return on Assets

5.18%

Free Cashflow Yield

3.07%

BIIB Fundamentals

BIIB Revenue

Revenue (TTM)

10.0B

Revenue Y/Y

0.87%

Revenue Q/Q

3.03%

BIIB Earnings

Earnings (TTM)

1.5B

Earnings Y/Y

-106%

Earnings Q/Q

-111.51%

Price Action

Last 7 days

2.0%

Last 30 days

3.3%

Last 90 days

-7.6%

Trailing 12 Months

-17.2%

How does BIIB drawdown profile look like?

BIIB Financial Health

Current Ratio

1.68

Debt/Equity

0.47

Debt/Cashflow

0.2

BIIB Investor Care

Buy Backs (1Y)

0.82%

Diluted EPS (TTM)

10.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202310.1B10.0B10.0B0
202210.8B10.6B10.4B10.2B
202112.6B11.7B11.1B11.0B
202014.4B14.5B14.3B13.4B
201913.8B14.1B14.2B14.4B
201812.6B12.9B13.2B13.5B
201711.5B11.7B11.8B12.3B
201610.9B11.2B11.4B11.4B
201510.1B10.3B10.6B10.8B
20147.6B8.3B9.0B9.7B
20135.6B5.9B6.4B6.9B
20125.1B5.3B5.4B5.5B
20114.8B4.8B4.9B5.0B
20104.4B4.6B4.6B4.7B
20094.2B4.3B4.3B4.4B
20083.4B3.6B3.9B4.1B
20070003.2B

Latest Insider Trading transactions for BIIB

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 05, 2023
singhal priya
sold
-116,124
269
-431
head of development
Sep 01, 2023
singhal priya
sold (taxes)
-215,606
267
-807
head of development
Sep 01, 2023
mcdonnell michael r
acquired
-
-
5,285
evp, chief financial officer
Sep 01, 2023
singhal priya
acquired
-
-
1,668
head of development
Sep 01, 2023
mcdonnell michael r
sold (taxes)
-722,428
267
-2,704
evp, chief financial officer
Jul 03, 2023
singhal priya
sold
-22,912
282
-81.00
head of development
Jun 30, 2023
singhal priya
acquired
-
-
315
head of development
Jun 30, 2023
kramer robin
acquired
-
-
252
chief accounting officer
Jun 30, 2023
izzar rachid
acquired
-
-
504
head of global product strat.
Jun 30, 2023
izzar rachid
sold (taxes)
-69,503
284
-244
head of global product strat.

1–10 of 50

Which funds bought or sold BIIB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 07, 2023
Hudson Bay Capital Management LP
added
186
26,027,800
42,406,600
0.17%
Dec 06, 2023
Raleigh Capital Management Inc.
unchanged
-
-696
6,425
-%
Dec 06, 2023
CITIGROUP INC
reduced
-5.6
-9,917,810
56,994,000
0.04%
Dec 04, 2023
Phoenix Holdings Ltd.
sold off
-100
-617,772
-
-%
Dec 04, 2023
Trust Co
unchanged
-
-4,538
41,893
0.01%
Dec 01, 2023
B. Riley Wealth Advisors, Inc.
reduced
-9.08
-195,587
893,110
0.02%
Dec 01, 2023
Fortis Group Advisors, LLC
new
-
3,855
3,855
-%
Nov 29, 2023
Carmignac Gestion
reduced
-0.32
-8,888,660
79,442,000
1.46%
Nov 27, 2023
USA FINANCIAL FORMULAS
added
0.45
-227,097
2,196,410
3.28%
Nov 27, 2023
BANQUE PICTET & CIE SA
reduced
-38.99
-5,042,360
6,173,890
0.07%

1–10 of 42

Latest Funds Activity

Are funds buying BIIB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BIIB
No. of Funds

Schedule 13G FIlings of Biogen Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
8.32%
11,976,623
SC 13G/A
Feb 09, 2023
primecap management co/ca/
10.9%
15,700,576
SC 13G/A
Jan 24, 2023
blackrock inc.
9.9%
14,260,137
SC 13G/A
Mar 07, 2022
blackrock inc.
9.4%
13,736,954
SC 13G/A
Feb 10, 2022
primecap management co/ca/
10.73%
15,757,405
SC 13G/A
Feb 09, 2022
vanguard group inc
7.85%
11,537,299
SC 13G/A
Feb 08, 2022
blackrock inc.
9.4%
13,736,954
SC 13G
Feb 12, 2021
primecap management co/ca/
10.28%
15,822,066
SC 13G/A
Feb 10, 2021
vanguard group inc
7.73%
11,896,510
SC 13G/A
Jan 29, 2021
blackrock inc.
8.7%
13,419,601
SC 13G/A

Recent SEC filings of Biogen Inc

View All Filings
Date Filed Form Type Document
Nov 08, 2023
8-K
Current Report
Nov 08, 2023
8-K
Current Report
Nov 08, 2023
10-Q
Quarterly Report
Nov 03, 2023
4
Insider Trading
Oct 12, 2023
3
Insider Trading
Sep 28, 2023
SC 13D/A
13D - Major Acquisition
Sep 28, 2023
8-K/A
Current Report
Sep 28, 2023
4
Insider Trading
Sep 26, 2023
8-K
Current Report
Sep 06, 2023
4
Insider Trading

BIIB Fair Value

Loading...

Peers (Alternatives to Biogen Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
389.5B
102.8B
2.69% -12.25%
11.25
3.79
11.47% 80.74%
272.8B
59.3B
-0.63% -5.14%
17.88
4.63
0.58% -69.80%
162.5B
68.5B
-6.62% -44.42%
15.5
2.37
-31.38% -64.79%
144.0B
26.8B
-1.52% -4.93%
19.03
5.37
1.91% 10.69%
98.5B
27.4B
1.44% -10.10%
16.77
3.6
0.94% 76.21%
MID-CAP
11.0B
15.3B
7.32% 18.03%
-4.98
0.72
0.87% -71.24%
4.3B
1.6B
4.36% 1.49%
20.08
2.71
40.56% 266.27%
4.0B
4.7B
2.10% -7.72%
-978.12
0.86
5.74% 96.18%
2.7B
601.3M
24.99% 94.42%
20.1
4.52
24.02% 75.17%
2.7B
8.5B
1.81% -4.07%
-2.77
0.31
5.11% -479.13%
SMALL-CAP
1.4B
650.9M
10.34% -28.86%
-0.96
2.13
6.08% -185.21%
22.1M
-
-5.00% -65.05%
0.32
0.55
-19.54% 888.31%
15.2M
111.1M
27.41% 2089.90%
-0.96
0.14
-10.43% 84.90%
12.5M
-
39.62% -61.05%
-0.59
0.13
287.27% -145.15%
5.2M
20.0M
16.16% 1110.53%
-0.38
0.26
137.71% 66.04%

Biogen Inc News

Latest updates
Defense World09 Dec 202308:23 am19 hours ago
StockNews.com08 Dec 202304:41 pm34 hours ago
Nasdaq08 Dec 202304:30 pm34 hours ago
MarketBeat08 Dec 202301:19 pm38 hours ago
MarketBeat08 Dec 202311:25 am40 hours ago
London South East06 Dec 202311:31 pm3 days ago
Yahoo Finance30 Nov 202308:00 am9 days ago
Nasdaq27 Nov 202308:00 am12 days ago
MarketBeat21 Nov 202308:00 am18 days ago
Yahoo Finance17 Nov 202308:00 am22 days ago
MarketWatch15 Nov 202309:59 pm24 days ago
Insider Monkey14 Nov 202302:49 am26 days ago
Bloomberg08 Nov 202308:00 am31 days ago
Nasdaq08 Nov 202308:00 am31 days ago

Financials for Biogen Inc

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue3.0%2,5302,4562,4632,5442,5092,5892,5322,7342,7792,7752,6942,8533,3763,6823,5343,6713,6003,6173,4903,5263,439
Costs and Expenses52.8%2,6721,7482,0251,9401,1371,3202,1842,5822,4882,1931,7202,6862,2901,7071,7141,8941,7941,6611,9872,0831,741
  S&GA Expenses43.8%788548605633563573635788654637595806573555570665555588568591498
EBITDA Margin-39.5%0.23*0.38*0.44*0.43*0.40*0.29*0.22*0.23*--0.36*0.43*0.48*0.54*0.53*0.54*0.56*----
Interest Expenses29.9%64.0049.0063.0055.0060.0066.0066.0066.0066.0056.0065.0056.0056.0066.0044.0046.0046.0048.0048.0049.0049.00
Income Taxes-163.5%-72.9011551.0054.00236217126443-25.90-40944.0013.00241446292276211248423470370
Earnings Before Taxes-119.9%-1417084386041,3711,2703474052915824673539582,0381,6991,7281,7791,7591,8601,4151,813
EBT Margin-48.6%0.16*0.31*0.36*0.35*0.33*0.22*0.15*0.16*0.15*0.20*0.30*0.38*0.45*0.50*0.48*------
Net Income-111.5%-68.105923885501,1351,0583043683294494103587021,5421,3991,4401,5461,4941,4099471,444
Net Income Margin-45.3%0.15*0.27*0.31*0.30*0.28*0.19*0.13*0.14*0.14*0.16*0.24*0.30*0.36*0.41*0.41*------
Free Cashflow24.6%518416389-2616027001047877631,155676-4531,0971,8441,318------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets12.1%28,19325,15724,59824,55424,85425,08123,61423,87723,80724,47023,85524,61924,93425,51226,11927,23427,48426,28826,44625,28925,492
  Current Assets-19.0%8,45410,4329,7639,7919,7669,7417,9167,8577,1627,1846,7206,8877,8438,4948,0078,3828,4487,9108,9437,6418,719
    Cash Equivalents-12.6%2,2882,6182,8983,4193,6762,6471,7492,2611,5421,7421,2181,3312,2252,3852,5912,9142,3441,7232,2431,2252,387
  Inventory123.7%2,9821,3341,2811,3441,3751,2941,2151,3521,3481,2551,1721,0691,028953859804752777770930917
  Net PPE-0.2%3,3023,3073,3013,2993,2663,3553,3733,4163,4113,4423,4383,4123,3603,3313,2823,2473,1383,0783,0143,6013,539
  Goodwill18.3%6,8085,7545,7525,7495,7415,7505,7585,7615,7615,7645,7635,7625,7565,7515,7525,7585,7465,7495,6405,7065,440
Liabilities28.2%13,71410,69610,81111,16612,08713,21812,39412,91812,92513,25613,19213,93314,19014,22313,58213,89513,49213,33912,62412,25711,732
  Current Liabilities57.6%5,0223,1873,0153,2733,9265,0183,9474,2984,2123,3473,1663,7423,8043,4474,6394,8644,4323,2113,1493,2953,175
  Long Term Debt8.0%6,7866,2856,2836,2816,2796,2776,2766,2746,2727,2697,2677,4267,4257,4244,4604,4594,4585,9495,9435,9375,931
Shareholder's Equity0.1%14,48014,46713,78713,39812,77611,86311,22110,96010,88211,21510,66310,68610,74511,28912,53713,33913,99212,94913,82213,03213,767
  Retained Earnings-0.4%17,37817,44616,85416,46715,91614,96014,21613,91213,54413,90113,83413,97613,96114,46715,67316,45517,06516,18317,02716,25716,944
  Additional Paid-In Capital41.9%24217191.0073.00--11968.00------0.00-----48.00
Shares Outstanding-100.0%-145144-144146147-148150152154157161173178184190197200201
Minority Interest35.9%-4.10-6.40-9.60-9.50-8.70-9.10-21.6064.00452463-19.00-14.20-14.00-19.50-10.00-4.10-4.10-4.10-7.90-8.00-6.80
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations21.6%592487455-1756617371628388051,227769-3671,1811,9491,4671,9601,6951,9641,4601,8951,736
  Share Based Compensation12.6%-64.80-74.1076.00189-65.70-58.0068.00170-57.60-55.8070.00132-35.40-49.5068.00139-47.80-55.0046.0035.0040.00
Cashflow From Investing-131.2%-1,742-753-953-1411,672694-648-112-233-152-64.70-166-52.40-832443708-365-110239-1,625-619
Cashflow From Financing8759.2%849-9.80-43.40-7.40-1,251-471-16.5010.00-746-564-785-401-1,312-1,313-2,245-2,116-689-2,375-679-1,43725.00
  Buy Backs-----250500--7504506004001,2502,8092,2202,0937182,4026561,353-

BIIB Income Statement

2023-09-30
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total revenue$ 2,530.3$ 2,508.5$ 7,449.3$ 7,629.4
Cost and expenses:    
Cost of sales, excluding amortization and impairment of acquired intangible assets659.6469.51,915.11,707.4
Research and development736.3549.21,891.11,629.5
Selling, general and administrative788.2563.31,941.21,770.8
Amortization and impairment of acquired intangible assets60.956.5164.0190.9
Collaboration profit sharing/(loss reimbursement)50.545.3164.5(42.6)
(Gain) loss on fair value remeasurement of contingent consideration0.0(2.1)0.0(13.7)
Restructuring charges76.015.4120.0124.1
Gain on sale of building0.0503.70.0503.7
Other (income) expense, net300.0(56.0)248.2(221.3)
Total cost and expense2,671.51,137.46,444.14,641.4
Income (loss) before income tax (benefit) expense and equity in loss of investee, net of tax(141.2)1,371.11,005.22,988.0
Income tax (benefit) expense(72.9)236.292.6578.5
Equity in (income) loss of investee, net of tax0.00.00.0(2.6)
Net income (loss)(68.3)1,134.9912.62,412.1
Net income (loss) attributable to noncontrolling interests, net of tax(0.2)0.21.2(84.4)
Net income (loss) attributable to Biogen Inc.$ (68.1)$ 1,134.7$ 911.4$ 2,496.5
Net income per share:    
Basic earnings (loss) per share attributable to Biogen Inc.$ (0.47)$ 7.86$ 6.30$ 17.12
Diluted earnings (loss) per share attributable to Biogen Inc.$ (0.47)$ 7.84$ 6.26$ 17.07
Weighted-average shares used in calculating:    
Basic earnings (loss) per share attributable to Biogen Inc.144,800144,400144,700145,800
Diluted earnings (loss) per share attributable to Biogen Inc.144,800144,800145,500146,200
Product, net    
Total revenue$ 1,805.2$ 1,962.1$ 5,414.3$ 6,083.3
LEQEMBI Collaboration    
Cost and expenses:    
Selling, general and administrative38.7   
Revenue from anti-CD20 therapeutic programs    
Total revenue420.9416.91,253.81,252.6
Contract manufacturing, royalty and other revenue    
Total revenue$ 304.2$ 129.5$ 781.2$ 293.5

BIIB Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 2,287.9$ 3,419.3
Marketable securities0.01,473.5
Inventory2,982.41,344.4
Other current assets974.11,417.6
Total current assets8,454.19,791.2
Marketable securities0.1705.7
Property, plant and equipment, net3,301.63,298.6
Operating lease assets460.9403.9
Intangible assets, net7,344.61,850.1
Goodwill6,807.55,749.0
Deferred tax asset1,069.81,226.4
Investments and other assets754.61,529.2
Total assets28,193.224,554.1
Current liabilities:  
Current portion of term loan500.00.0
Taxes payable243.8259.9
Accounts payable440.1491.5
Accrued expense and other3,838.42,521.4
Total current liabilities5,022.33,272.8
Notes payable and term loan6,786.46,281.0
Deferred tax liability728.1334.7
Long-term operating lease liabilities428.8333.0
Other long-term liabilities747.9944.2
Total liabilities13,713.511,165.7
Commitments, contingencies and guarantees
Biogen Idec Inc. shareholders' equity  
Preferred stock, par value $0.001 per share0.00.0
Common stock, par value $0.0005 per share0.10.1
Additional paid-in capital242.273.3
Accumulated other comprehensive income (loss)(159.3)(164.9)
Retained earnings17,377.916,466.5
Treasury stock, at cost(2,977.1)(2,977.1)
Total Biogen Inc. shareholders’ equity14,483.813,397.9
Noncontrolling interests(4.1)(9.5)
Total equity14,479.713,388.4
Total liabilities and equity28,193.224,554.1
Nonrelated Party  
Current assets:  
Accounts receivable, net1,781.41,705.0
Related Party  
Current assets:  
Accounts receivable, net$ 428.3$ 431.4
BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.biogen.com
 EMPLOYEES8725

Biogen Inc Frequently Asked Questions


What is the ticker symbol for Biogen Inc? What does BIIB stand for in stocks?

BIIB is the stock ticker symbol of Biogen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biogen Inc (BIIB)?

As of Fri Dec 08 2023, market cap of Biogen Inc is 34.63 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIIB stock?

You can check BIIB's fair value in chart. The fair value of Biogen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biogen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIIB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biogen Inc a good stock to buy?

The fair value guage provides a quick view whether BIIB is over valued or under valued. Whether Biogen Inc is cheap or expensive depends on the assumptions which impact Biogen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIIB.

What is Biogen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, BIIB's PE ratio (Price to Earnings) is 23.69 and Price to Sales (PS) ratio is 3.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIIB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Biogen Inc's stock?

In the past 10 years, Biogen Inc has provided -0.009 (multiply by 100 for percentage) rate of return.